This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany

Bold Therapeutics Inc.


Bold Therapeutics Inc. is a clinical-stage oncology company developing BOLD-100, a first-in-class Phase 2 small molecule therapeutic with a unique mechanism-of-action. BOLD-100 significantly enhances the activity of a wide range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival and proliferation pathway. Interim Phase 2 results show that BOLD-100 significantly improves both progression-free survival (PFS) and overall survival (OS) in advanced metastatic colorectal cancer (mCRC) relative to existing therapies. Preliminary efficacy data in bile duct, gastric and pancreatic cancers is expected to be available shortly.